7. Literaturverzeichnis

1. Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, Weiner LM: Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res. 58, 485-490 (1998)

2. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, Weiner LM: High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 61, 4750-4755 (2001)

3. Adams GP, Tai MS, McCartney JE, Marks JD, Stafford WF 3rd, Houston LL, Huston JS, Weiner LM. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res. 12, 1599-1605 (2006)

4. Amadori S, Suciu S, Stasi R, Willemze R, Mandelli F, Selleslag D, Denzlinger C, Muus P, Stauder R, Berneman Z, Pruijt J, Nobile F, Cassibba V, Marie JP, Beeldens F, Baila L, Vignetti M, de Witte T: Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups. Leukemia 19, 1768-73 (2005)

5. Anagnostopoulos I, Hansmann ML, Franssila K, Harris M, Harris NL, Jaffe ES, Han J, van Krieken JM, Poppema S, Marafioti T, Franklin J, Sextro M, Diehl V, Stein H: European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 96, 1889-1899 (2000)

6. Ansén S, Engert A, Wolf J, Sieber M, Paulus U, Diehl V: Deutsche Hodgkin-Lymphom Studiengruppe (DHSG): 20 Jahre Diagnostik, Therapie und Nachsorge von Patienten mit Morbus Hodgkin. Onkologie 24 Suppl 1, 35-48 (2001)

7. Arndt MA, Krauss J, Kipriyanov SM, Pfreundschuh M, Little M. A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors. Blood. 94, 2562-2568 (1999)

8. Azinovic I, DeNardo GL, Lamborn KR, Mirick G, Goldstein D, Bradt BM, DeNardo SJ. Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies. Cancer Immunol Immunother. 55, 1451-1458 (2006)

9. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmüller G, Reinhardt C, Baeuerle PA, Kufer P: Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321, 974-977 (2008)

10. Blumenthal RD, Fand I, Sharkey RM, Boerman OC, Kashi R, Goldenberg DM: The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: an autoradiographic study. Cancer Immunol Immunother. 33, 351-358 (1991)

11. Bolhassani A, Rafati S: Heat-shock proteins as powerful weapons in vaccine development. Expert Rev Vaccines 7, 1185-99 (2008)

12. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C: Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36, 252-9 (1975)

13. Bonadonna G: Chemotherapy strategies to improve the control of Hodgkin's disease: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 42, 4309-20 (1982)

14. Boven E, Lindmo T, Mitchell JB, Bunn PA Jr: Selective cytotoxicity of 125I-labeled monoclonal antibody T101 in human malignant T cell lines. Blood 67, 429-35 (1986)

15. Brichard VG, Lejeune D: GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine. 25 Suppl 2, 61-71 (2007)

16. Burges A, Wimberger P, Kümper C, Gorbounova V, Sommer H, Schmalfeldt B, Pfisterer J, Lichinitser M, Makhson A, Moiseyenko V, Lahr A, Schulze E, Jäger M, Ströhlein MA, Heiss MM, Gottwald T, Lindhofer H, Kimmig R: Effective Relief of Malignant Ascites with Advanced Ovarian Cancer by Trifunctional Anti-EpCAM x Anti-CD3 Antibody: A PhaseI/II Study. Clin Cancer Res. 13, 3899-3905 (2007)

17. Buske C, Feuring-Buske M, Antonchuk J, Rosten P, Hogge DE, Eaves CJ, Humphries RK. Overexpression of HOXA10 perturbs human lymphomyelopoiesis in vitro and in vivo. Blood. 97, 2286-2292 (2001)

18. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulières D, Cormier Y, Ellis P, Price A, Sawhney R, Davis M, Mansi J, Smith C: Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer. J Clin Oncol. 23, 6674-6681 (2005)

19. Caillard S, Agodoa LY, Bohen EM, Abbott KC. Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: characteristics, risk factors and prognosis. Transplantation. 81, 888-895 (2006)

20. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 327, 1478-84 (1992)

21. Canevari S, Mezzanzanica D, Mazzoni A, Negri DR, Ramakrishna V, Bolhuis RL, Colnaghi MI, Bolis G: Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions. J Hematother. 4, 423-427 (1995)

22. Carrasquillo JA, Mulshine JL, Bunn PA Jr, Reynolds JC, Foon KA, Schroff RW, Perentesis P, Steis RG, Keenan AM, Horowitz M, et al.: Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphoma. J Nucl Med. 28, 281-287 (1987)

23. Cartwright RA, Watkins G.: Epidemiology of Hodgkin's disease: a review. Hematol Oncol. 22, 11-26 (2004)

24. Catimel B, Ritter G, Welt S, Old LJ, Cohen L, Nerrie MA, White SJ, Heath JK, Demediuk B, Domagala T, Lee FT, Scott AM, Tu GF, Ji H, Moritz RL, Simpson RJ, Burgess AW, Nice EC: Purification and characterization of a novel restricted antigen expressed by normal and transformed human colonic epithelium, J Biol Chem. 271, 25664-70 (1996)

25. Clark JI, Alpaugh RK, von Mehren M, Schultz J, Gralow JR, Cheever MA, Ring DB, Weiner LM: Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment. Cancer Immunol Immunother. 44, 265-272 (1997)

26. Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM. In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice. Cancer Res. 60, 4804-4811 (2000)

27. Coley W: The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigius). London: John Bale & Sons Publishers 1909; 1–48 (1909)

28. Collet B, Maros S, Moisan A, Le Cloirec J, Moinereau M, Aumaitre E, Toujas L, Bourguet P: 111Indium-F(ab)'2-NCA 102 monoclonal antibody: In vitro study of a specific agent for the detection of inflammatory foci. Nucl Med Biol. 20, 175-182 (1993)

29. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 351, 337-345 (2004)

30. da Costa L, Renner C, Hartmann F, Pfreundschuh M.Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease. Cancer Chemother Pharmacol. 46 Suppl, 33-36 (2000)

31. Davis TA, Grillo-López AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 18, 3135-43 (2000)

32. Davies AJ: Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab. Oncogene. 26, 3614-3628 (2007)

33. Devita VT Jr, Serpick AA, Carbone PP: Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 73, 881-895 (1970)

34. Deyev SM, Lebedenko EN: Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design. Bioessays. 30, 904-918 (2008)

35. Diehl V, von Kalle C, Fonatsch C, Tesch H, Jüecker M, Schaadt M: The cell of origin in Hodgkin's disease. Semin Oncol. 17, 660-672 (1990)

36. Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rueffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-Jahn U, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Duehmke E, Georgii A, Loeffler M: BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma. J Clin Oncol. 16, 3810-3821 (1998)

37. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, Dörken B, Müller-Hermelink HK, Dühmke E, Loeffler M; German Hodgkin's Lymphoma Study Group: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 348, 2386-2395 (2003)

38. Diehl V: Hodgkin's disease-from pathology specimen to cure. N Engl J Med. 357, 1968-1971 (2007)

39. Diehl V, Fuchs M; GHSG: Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages? Transfus Apher Sci. 37, 37-41 (2007)

40. Dillman R: Antibodies as cytotoxic therapy. J Clin Oncol. 12, 1497-1515 (1994)

41. Dillman R: Monoclonal antibody therapy for lymphoma: an update. Cancer Pract. 9, 71-80 (2001)

42. Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, Kufer P, Riethmuller G, Bargou R, Baeuerle PA: Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer. 100, 690-697 (2002)

43. Duncan JR, Stephenson MT, Wu HP, Anderson CJ: Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. Cancer Res. 57, 659-671 (1997)

44. Ellis TM, Simms PE, Slivnick DJ, Jäck HM, Fisher RI: CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J Immunol. 151, 2380-2389 (1993)

45. Engert A, Burrows F, Jung W, Tazzari PL, Stein H, Pfreundschuh M, Diehl V, Thorpe P: Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease. Cancer Res. 50, 84-88 (1990)

46. Engert A, Diehl V, Schnell R, Radszuhn A, Hatwig MT, Drillich S, Schön G, Bohlen H, Tesch H, Hansmann ML, Barth S, Schindler J, Ghetie V, Uhr J, Vitetta E: A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood. 89, 403-410 (1997)

47. Fanger MW, Graziano RF, Guyre PM: Production and use of anti-FcR bispecific antibodies. Immunomethods. 4, 72-81 (1994)

48. Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Diviné M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M; EORTC-GELA H8 Trial: Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 357, 1916-1927 (2007)

49. Ferrini S, Prigione I, Miotti S, Ciccone E, Cantoni C, Chen Q, Colnaghi MI, Moretta L: Bispecific monoclonal antibodies directed to CD16 and to a tumor-associated antigen induce target-cell lysis by resting NK cells and by a subset of NK clones Int J Cancer. 48, 227-233 (1991)

50. Fischer N, Leger O: Bispecific Antibodies: Molecules that enable therapeutic Strategies. Pathobiology 74, 3-14 (2007)

51. Flieger D, Renoth S, Beier I, Sauerbruch T, Schmidt-Wolf I. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol. 204, 55-63 (2000)

52. Foss HD, Marafioti T, Stein H: Hodgkin-Lymphome Klassifikation und Pathogenese. Der Pathologe 21, 113-123 (2000)

53. Fujimori K, Covell DG, Fletcher JE, Weinstein JN: A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med. 31, 1191-1198 (1990)

54. Garrido MA, Valdayo MJ, Winkler DF, Titus JA, Hecht TT, Perez P, Segal DM, Wunderlich JR: Targeting human T-lymphocytes with bispecific antibodies to react

against human ovarian carcinoma cells growing in nu/nu mice. Cancer Res. 50, 4227-4232 (1990)

55. Gilfillan MC, Noel PJ, Podack ER, Reiner SL, Thompson CB: Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines. J Immunol. 160, 2180-2187 (1998)

56. Goodman LS 1946: Landmark article Sept. 21, 1946: Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. By Louis S. Goodman, Maxwell M. Wintrobe, William Dameshek, Morton J. Goodman, Alfred Gilman and Margaret T. McLennan. JAMA. 251, 2255-2261 (1984)

57. Grosse-Hovest L, Brandl M, Dohlsten M, Kalland T, Wilmanns W, Jung G: Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: the role of targeted T-cell co-stimulation via CD28. Int J Cancer. 80, 138-44 (1999)

58. Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG: Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood. 83, 2045-2056 (1994)

59. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Müller-Hermelink H-K, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 84, 1361–1392 (1994)

60. Hartmann F, Renner C, Jung W, Deisting C, Juwana M, Eichentopf B, Kloft M, Pfreundschuh M: Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood. 89, 2042-2047 (1997)

61. Hartmann F, Renner C, Jung W, Pfreundschuh M: Anti-CD16/CD30 bispecific antibodies as possible treatment for refractory Hodgkin's disease. Leuk Lymphoma. 31, 385-92 (1998)

62. Hartmann F, Renner C, Jung W, da Costa L, Tembrink S, Held G, Sek A, König J, Bauer S, Kloft M, Pfreundschuh M: Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. Clin Cancer Res. 7, 1873-1881 (2001)

63. Heath JK, White SJ, Johnstone CN, Catimel B, Simpson RJ, Moritz RL, Tu GF, Ji H, Whitehead RH, Groenen LC, Scott AM, Ritter G, Cohen L, Welt S, Old LJ, Nice EC and Burgess AW: The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc Natl Acad Sci USA 94, 469-474 (1997)

64. Hericourt J, Richet C: 'Physiologie pathologique' - de la serotherapie dans le traitement du cancer. Comptes Rendus Hebd Seanc Acad Sci (Paris) 120, 567–569 (1895)

65. Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, Dölken G, Naumann R, Knauf W, Freund M, Rohrberg R, Höffken K, Franke A, Ittel T, Kettner E, Haak U, Mey U, Klinkenstein C, Assmann M, von Grünhagen U; East German Study Group Hematology and Oncology Study: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 25, 1986-1992 (2007)

66. Hodgkin T: On some morbid appearances of the absorbent glands and spleen. Medico-Chirurgical Transactions (London) 17, 68-114 (1832)

67. Hombach A, Jung W, Pohl C, Renner C, Sahin U, Schmits R, Wolf J, Kapp U, Diehl V, Pfreundschuh M: A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo. Int J Cancer. 55, 830-836 (1993)

68. Horn-Lohrens O, Tiemann M, Lange H, Kobarg J, Hafner M, Hansen H, Sterry W, Parwaresch RM, Lemke H: Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). Int J Cancer. 60, 539-544 (1995)

69. Hummel M, Anagnostopoulos I, Dallenbach F, Korbjuhn P, Dimmler C, Stein H: EBV infection patterns in Hodgkin's disease and normal lymphoid tissue: expression and cellular localization of EBV gene products. Br J Haematol. 82, 689-694 (1992)

70. Hummel M, Marafioti T, Stein H: Clonality of Reed-Sternberg cells in Hodgkin's disease. N Engl J Med. 340, 394-395 (1999)

71. Hunter WM, Greenwood FC: Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature. 194, 495-496 (1962)

72. Huston JS, George AJ, Adams GP, Stafford WF, Jamar F, Tai MS, McCartney JE, Oppermann H, Heelan BT, Peters AM, Houston LL, Bookman MA, Wolf EJ, Weiner LM: Single-chain Fv radioimmunotargeting. Q J Nucl Med. 40, 320-333 (1996)

73. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 350, 2335-2342 (2004)

74. Jäger M, Schoberth A, Ruf P, Hess J, Lindhofer H: The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Cancer Res. 69, 4270-4276. (2009)

75. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 48, 7022-7032 (1988)

76. Josting A, Nogová L, Franklin J, Glossmann JP, Eich HT, Sieber M, Schober T, Boettcher HD, Schulz U, Müller RP, Diehl V, Engert A: Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol. 23, 1522-1529 (2005)

77. Juweid M, Neumann R, Paik C, Perez-Bacete MJ, Sato J, van Osdol W, Weinstein JN: Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 52, 5144-5153 (1992)

78. Kalmar, J. R., Arnold, R. R., Warbington, M. L., Gardner, M. K: Superior leukocyte separation with a discontinuous one-step Ficoll-Hypaque gradient for the isolation of human neutrophils. J. Immunol. Meth. 110, 275-281 (1988)

79. Kapatai G, Murray P: Contribution of the Epstein–Barr virus to the molecular pathogenesis of Hodgkin lymphoma. J Clin Pathol. 60, 1342-1349 (2007)

80. Kaplan H: Role of intensive radiotherapy in the management of Hodgkin's disease. Cancer 19, 356 (1966)

81. Karlsruher Nuklidkarte, Marktdienste Haberbeck; Auflage: 6. Auflage. ISBN 3-921879-18-3 (1998)

82. Kiewe P, Hasmüller S, Kahlert S, Heinrigs M, Rack B, Marmé A, Korfel A, Jäger M, Lindhofer H, Sommer H, Thiel E, Untch M: Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res. 12, 3085-91 (2006)

83. Kiewe P, Thiel E.: Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs. 17, 1553-1558 (2008)

84. King DJ, Antoniw P, Owens RJ, Adair JR, Haines AM, Farnsworth AP, Finney H, Lawson AD, Lyons A, Baker TS, et al.: Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy. Br J Cancer. 72, 1364-1372 (1995)

85. Köhler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 256, 495-497 (1975)

86. Küppers R, Rajewsky K, Zhao M, Simons G, Laumann R, Fischer R, Hansmann ML: Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci USA. 91, 10962-10966 (1994)

87. Lee SY, Park CG, Choi Y: T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors. J Exp Med. 183, 669-674 (1996)

88. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr: Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 72, 77-89 (1984)

89. Longo DL, Young RC, Wesley M, Hubbard SM, Duffey PL, Jaffe ES, DeVita VT Jr: Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol. 4, 1295-306 (1986)

90. Loo L, Robinson MK, Adams GP: Antibody engineering principles and applications. Cancer J. 14, 149-153 (2008)

91. Maloney DG, Smith B, Rose A: Rituximab: mechanism of action and resistance. Semin Oncol. 29, 2-9 (2002)

92. Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC, Sotto JJ, Leroux D, Bensa JC, Plumas J: In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 101, 949-954 (2003)

93. McCall AM, Shahied L, Amoroso AR, Horak EM, Simmons HH, Nielson U, Adams GP, Schier R, Marks JD, Weiner LM: Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J Immunol. 166, 6112-6117 (2001)

94. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 16, 2825-2833 (1998)

95. Miller RA: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 306, 517–522 (1982)

96. Milstein C, Cuello AC: Hybrid hybridomas and their use in immunohistochemistry. Nature. 305, 537-540 (1983)

97. Miotti S, Negri DR, Valota O, Calabrese M, Bolhuis RL, Gratama JW, Colnaghi MI, Canevari S. Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival. Int J Cancer. 84, 62-68 (1999)

98. Nice EC, Catimel B: Instrumental biosensors: new perspectives for the analysis of biomolecular interactions. Bioessays. 21, 339-352 (1999)

99. Nikula TK, Curcio MJ, Brechbiel MW, Gansow OA, Finn RD, Scheinberg DA: A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies. Nucl Med Biol. 22, 387-390 (1995)

100. Nikula TK, McDevitt MR, Finn RD, Wu C, Kozak RW, Garmestani K, Brechbiel MW, Curcio MJ, Pippin CG, Tiffany-Jones L, Geerlings MW Sr, Apostolidis C, Molinet R, Geerlings MW Jr, Gansow OA, Scheinberg DA: Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med. 40, 166-176 (1999)

101. Nogava L, Reineke T, Brillant C, Sieniawski M, Rüder T, Josting A, Bredenfeld H, Skripnitchenko R, Müller rp, Mülle-Hermelink HK, Diehl V, Engert A: Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. Journal of Clinical Oncology. 26, 434-439 (2008)

102. Odashiro DN, Odashiro AN, Pereira PR, Godeiro K, Antecka E, Di Cesare S, Burnier MN Jr: Expression of EpCAM in uveal melanoma. Cancer Cell Int. 26, 1-5 (2006)

103. Offringa R, van der Burg SH, Ossendorp F, Toes RE, Melief CJ: Design and evaluation of antigen-specific vaccination strategies against cancer. Curr Opin Immunol. 12, 576–582 (2000)

104. Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan CC, Carroll MW, Moss B, Rosenberg SA, Restifo NP: Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci USA. 96, 2982-2987 (1999)

105. Oza AM, Ganesan TS, Leahy M, Gregory W, Lim J, Dadiotis L, Barbounis V, Jones AE, Amess J, Stansfeld AG, et al.: Patterns of survival in patients with Hodgkin's disease: long follow up in a single centre. Ann Oncol. 4, 385-392 (1993)

106. Panousis C, Rayzman VM, Johns TG, Renner C, Liu Z, Cartwright G, Lee FT, Wang D, Gan H, Cao D, Kypridis A, Smyth FE, Brechbiel MW, Burgess AW, Old LJ, Scott AM. Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR. Br J Cancer. 92, 1069-1077 (2005)

107. Parks DR, Hardy RR, Herzenberg LA: Three-color immunofluorescence analysis of mouse B-lymphocyte subpopulations. Cytometry. 5, 159-168 (1984)

108. Parulekar WR, Eisenhauer EA: Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst. 96, 990-997 (2004)

109. Patel D, Lahiji A, Patel S, Franklin M, Jimenez X, Hicklin DJ, Kang X.Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface. Anticancer Res. 27, 3355-3366 (2007)

110. Pavlinkova G, Beresford GW, Booth BJ, Batra SK, Colcher D. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts. J Nucl Med. 40, 1536-1546 (1999)

111. Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M; MabThera International Trial Group: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 7, 379-91 (2006)

112. Pohl C, Denfeld R, Renner C, Jung W, Bohlen H, Sahin U, Hombach A, van Lier R, Schwonzen M, Diehl V, et al: CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma. Int J Cancer. 54, 820-827 (1993)

113. Press OW, Shan D, Howell-Clark J, Eary J, Appelbaum FR, Matthews D, King DJ, Haines AM, Hamann P, Hinman L, Shochat D, Bernstein ID. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res. 56, 2123-2129 (1996)

114. Reed DM.: On the pathological changes in Hodgkin's disease, with special reference to its relation to tuberculosis. Johns Hopkins Hosp Rep. 10, 133 (1902)

115. Rehwald U, Schulz H, Reiser M, Sieber M, Staak JO, Morschhauser F, Driessen C, Rudiger T, Muller-Hermelink K, Diehl V, Engert A; German Hodgkin Lymphoma Study Group (GHSG). Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood. 101, 420-424 (2003)

116. Renner C, Jung W, Sahin U, Denfeld R, Pohl C, Trümper L, Hartmann F, Diehl V, van Lier R, Pfreundschuh M: Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science. 264, 833-835 (1994)

117. Renner C, Pfreundschuh M: Tumor therapy by immune recruitment with bispecific antibodies. Immunol Rev. 145, 179-209 (1995)

118. Renner C, Bauer S, Sahin U, Jung W, van Lier R, Jacobs G, Held G, Pfreundschuh M. Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model. Blood. 87, 2930-2937 (1996)

119. Renner C, Held G, Ohnesorge S, Bauer S, Gerlach K, Pfitzenmeier JP, Pfreundschuh M. Role of naive and memory T cells in tumor cell lysis mediated by bi-specific antibodies. Immunobiology. 197, 122-132 (1997)

120. Renner C, Hartmann F, Jung W, Deisting C, Juwana M, Pfreundschuh M: Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's

disease by treatment with an anti-CD16/CD30 bispecific antibody. Cancer Immunol Immunother. 49, 173-180 (2000)

121. Renner C, Hartmann F, Pfreundschuh M. Immuntherapeutische Strategien zur Behandlung solider Tumoren. Dt. Ärzteblatt. 99, 850-858 (2002)

122. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355, 2542–2550 (2006)

123. Sangha R, Butts C: L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res. 13, 4652-4654 (2007)

124. Scatchard G: Attractions of Proteins for small molecules and ions. Ann NY Acad Sci. 51, 660-672 (1949)

125. Schlapschy M, Gruber H, Gresch O, Schäfer C, Renner C, Pfreundschuh M, Skerra A: Functional humanization of an anti-CD30 Fab fragment for the immunotherapy of Hodgkin's lymphoma using an in vitro evolution approach. Protein Eng Des Sel. 17, 847-860 (2004)

126. Schlapschy M, Fogarasi M, Gruber H, Gresch O, Schäfer C, Aguib Y, Skerra A: Functional humanization of an anti-CD16 Fab fragment: obstacles of switching from murine {lambda} to human {lambda} or {kappa} light chains. Protein Eng Des Sel. 22, 175-188 (2009)

127. Schlereth B, Quadt C, Dreier T, Kufer P, Lorenczewski G, Prang N, Brandl C, Lippold S, Cobb K, Brasky K, Leo E, Bargou R, Murthy K, Baeuerle PA: T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol Immunother. 55, 503-514 (2006)

128. Schnell R, Linnartz C, Katouzi AA, Schön G, Bohlen H, Horn-Lohrens O, Parwaresch RM, Lange H, Diehl V, Lemke H, et al.: Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen. Int J Cancer. 63, 238-244. (1995)

129. Schnell R, Staak O, Borchmann P, Schwartz C, Matthey B, Hansen H, Schindler J, Ghetie V, Vitetta ES, Diehl V, Engert A: A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res. 8, 1779-1786 (2002)

130. Schnell R, Dietlein M, Schomäcker K, Kobe C, Borchmann P, Schicha H, Hallek M, Engert A. Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma. Onkologie. 31, 49-51. (2008)

131. Schreiber GJ, Hellström KE, Hellström I: An unmodified anticarcinoma antibody, BR96, localizes to and inhibits the outgrowth of human tumors in nude mice. Cancer Res. 52, 3262-3266 (1992)

132. Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rüdiger T, Borchmann P, Schnell R, Diehl V, Engert A, Reiser M: Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 111, 109-111 (2008)

133. Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M, Diehl V: Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells

of Hodgkin's disease and a subset of normal lymphoid cells. Nature. 299, 65-67 (1982)

134. Scott AM, Welt S: Antibody-based immunological therapies. Curr Opin Immunol. 9, 717-22 (1997)

135. Segal DM, Qian JH, Mezzanzanica D, Garrido MA, Titus JA, Andrew SM, George AJ, Jost CR, Perez P, Wunderlich JR: Targeting of anti-tumor responses with bispecific antibodies. Immunobiology. 185, 390-402 (1992)

136. Shan D, Ledbetter JA, Press OW: Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother. 48, 673-683 (2000)

137. Sharkey RM, Motta-Hennessy C, Pawlyk D, Siegel JA, Goldenberg DM: Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res. 50, 2330-2336 (1990)

138. Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin. 56, 226-243 (2006)

139. Sharkey RM, Goldenberg DM. Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv Drug Deliv Rev. 60, 1407-1420. (2008)

140. Shih LB, Thorpe SR, Griffiths GL, Diril H, Ong GL, Hansen HJ, Goldenberg DM, Mattes MJ: The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J Nucl Med. 35, 899-908 (1994)

141. Sieber M Rüffler U, Diehl V: Aktuelle Therapiesrategien beim Morbus Hodgkin. Morbus Hodgkin und Non-Hodgkin-Lymphome. 2. überarbeitete Auflage (1998)

142. Sieber M, Rüffer U, Josting A, Diehl V: Treatment of Hodgkin's disease: current strategies of the German Hodgkin's Lymphoma Study Group. Ann Oncol. 1999;10 Suppl 6:23-9. Review. Erratum in: Ann Oncol. 11, 765 (2000)

143. Smith CA, Gruss HJ, Davis T, Anderson D, Farrah T, Baker E, Sutherland GR, Brannan CI, Copeland NG, Jenkins NA, et al.: CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell. 73, 1349-1360 (1993)

144. Specht L, Gray RG, Clarke MJ, Peto R: Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol. 16, 830-843 (1998)

145. Staerz UD, Yewdell JW, Bevan MJ: Hybrid antibody-mediated lysis of virus-infected cells. Eur J Immunol. 17, 571-574 (1987)

146. Sternberg C.: Über eine eigenartige unter dem Bilde der Pseudoleukämie verlaufende Tuberculose des lymphatischen Apparates. Zeitschrift für Heilkunde 19, 21 (1898)

147. Stiefenhagen P et al.: Morbus Hodgkin-Aktuelle Aspekte zur Pathogenes und Therapie. Internist. 39, 668-674 (1998)

148. Sun Y, Paschen A, Schadendorf D: Cell-based vaccination against melanoma--background, preliminary results, and perspective. J Mol Med. 77, 593-608 (1999)

149. Suto R, Srivastava PK: A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science. 269, 1585-1588 (1995)

150. Tahtis K, Lee FT, Smyth FE, Power BE, Renner C, Brechbiel MW, Old LJ, Hudson PJ, Scott AM. Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model. Clin Cancer Res. 7, 1061-1072 (2001)

151. Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Ernstoff MS, Wells W, Barth R, Deo Y, Fisher J, et al.: Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu. J Hematother. 4, 471-475 (1995)

152. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 359, 1116-1127 (2008)

153. Viviani S, Bonadonna G, Santoro A, Bonfante V, Zanini M, Devizzi L, Soncini F, Valagussa P: Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol. 14, 1421-1430 (1996)

154. Weiner LM, Clark JI, Ring DB, Alpaugh RK: Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. J Hematother. 4, 453-456 (1995)

155. Weinstein JN, van Osdol W. Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding site barrier". Cancer Res. 52, 2747s-2751s (1992)

156. Welt S, Divgi CR, Real FX, Yeh SD, Garin-Chesa P, Finstad CL, Sakamoto J, Cohen A, Sigurdson ER, Kemeny N, et al.. Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33. J Clin Oncol. 8, 1894-1906 (1990)

157. Wilhelm C, Neubauer A: Molekulare Tumortherapie. Internist 49, 581-592 (2008)

158. Winkler U, Gottstein C, Schön G, Kapp U, Wolf J, Hansmann ML, Bohlen H, Thorpe P, Diehl V, Engert A. Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins. Blood. 83, 466-475 (1994)

159. Wolf E, Hofmeister R, Kufer P, Schlereth B, Baeuerle PA: BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today. 10, 1237-1244 (2005)

160. Wu C, Kobayashi H, Sun B, Yoo TM, Paik CH, Gansow OA, Carrasquillo JA, Pastan I, Brechbiel MW: Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA. Bioorg Med Chem. 5, 1925-34 (1997)

161. Zambelli A, Lilleri D, Baldanti F, Scelsi M, Villani L, Da Prada GA.: Hodgkin's disease as unusual presentation of post-transplant lymphoproliferative disorder after autologous hematopoietic cell transplantation for malignant glioma. BMC Cancer. 5, 109 (2005)